Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Abbott Laboratories : Cyber Insurance Becomes a Must for More Manufacturers

share with twitter share with LinkedIn share with facebook
share via e-mail
1
04/17/2017 | 01:15pm CEST
By Richard Teitelbaum 

Abbott Laboratories was pilloried last week by regulators for, in part, botching its response to a report that certain company defibrillators and pacemakers could be manipulated by hackers. Shares of the health-care giant, which acquired the devices in its purchase of St. Jude Medical Inc., fell 1.9%.

The criticism, which came in a warning letter from the U.S. Food and Drug Administration, casts another spotlight on the fusillade of cyber dangers facing manufacturers.

For years cyber insurance was overwhelmingly purchased by consumer-facing business -- retailers, financial-service providers and hospitals. Mostly this was to protect against customer data theft. The St. Jude situation helps explain why manufacturers are now rushing to make sure they are covered.

Manufacturers paid $36.9 million in premiums for cyber-specific policies in 2016, according to Advisen Ltd., an insurance consulting firm, based on its sample of over 9,000 mostly U.S. companies. That is up 89% from the year before. Manufacturers accounted for 12.6% premiums tracked in 2016 compared with 9% the year before.

"There's certainly an increased exposure in the industry overall, especially with more reliance on cloud providers, greater sophistication of hackers globally and increased consumer interactions through social media," said Daniel Steiner, enterprise risk manager at Kimberly-Clark Corp., the maker of Kleenex tissues and Huggies diapers. The company began buying cyber insurance in 2009.

Factories are increasingly computerized, automated and digitally integrated with other parts of a company and keeping those networks secure is critical. "It's hard to think of an area of our business that is not touched by this, as business is only becoming more connected," said Eric Dobkin, director of insurance and risk management at drugmaker Merck & Co. in an email.

"Nobody should be able to look at themselves in the mirror and say 'I'm not exposed to this'," said Robert Wice, leader for technology, media and business services of Beazley PLC in the U.S. "It should be top of mind."

As for St. Jude, a company spokeswoman declined to say whether it carried cyber insurance to cover the cardiac devices. A 2016 filing said it did not carry product liability insurance. An Abbott spokesman declined to comment on whether the company has cyber insurance.

In the event of a cyberattack that shuts down a factory, manufacturers may not be covered by existing policies. Many property and casualty, or P&C, policies require physical damage before they pay, explained Ben Beeson, cyberrisk practice leader at brokerage Lockton Cos.

A wake-up call for manufacturers came in December 2014 when the German Federal Office for Information Security reported that a cyberattack caused "massive damage" at a steel plant it didn't name.The report highlighted how cyberattacks can be more destructive than prosaic events like floods that are covered by typical P&C policies.

"When you look at severity, you have to consider they are cyber-based," said Brent Pickens, director of global risk management at Bemis Co. Inc., a maker of plastic packaging that was an early buyer of cyber insurance.

Selecting a cyberpolicy forces manufacturers to set priorities on what to protect, he said, particularly at larger companies that can have policies tailored for different plants and situations. "You get the best return out of [insuring] what is most important for you," Mr. Pickens added.

The market for manufacturers is young, therefore premiums vary greatly and are based on revenue, specific lines of business, and the number of records involved. Premiums range from $10,000 to $15,000 for every $1 million of comprehensive coverage for manufacturers with $1 billion or more in revenue, said Michael Blake, part of the cybersecurity practice at Alliant Insurance Services Inc. That is about half of what retailers and banks pay.

"It's not a difficult sell," said Mr. Blake."There is not a risk manager out there who wants to walk into a board meeting to explain why he didn't think to get a cyber insurance quote, especially since it's so cheap."

Write to Richard Teitelbaum at Richard.Teitelbaum@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
1
Latest news on ABBOTT LABORATORIES
07/21 ABBOTT LABORATORIES : Today's Research Reports on Stocks to Watch: Abbott Labora..
07/21 ABBOTT LABORATORIES : $30,000 Federal Contract Awarded to Abbott Laboratories
07/20 PPG and C.H. Robinson slip while Abbott and Sears advance
07/20 Abbott profit forecast gets a lift from St. Jude integration
07/20 ABBOTT LABORATORIES (NYSE : ABT) reported earnings of $0.62 per share beating Wa..
07/20 ABBOTT LABORATORIES : revenue grows 4.4 percent, but pacemaker sales drop
07/20 ABBOTT LABORATORIES (NYSE : ABT) Files An 8-K Results of Operations and Financia..
07/20 ABBOTT LABORATORIES : tops Street 2Q forecasts
07/20 ABBOTT LABORATORIES : Results of Operations and Financial Condition, Financial S..
07/20 ABBOTT : Reports Second-Quarter 2017 Results
More news
News from SeekingAlpha
07/24 ABIOMED : This Debt-Free Medical Device Stock Is A Strong Buy In 2017
07/24 A REVIEW OF THE DIVIDEND HOUSE PORTF : Time For A House Inspection
07/21 WALL STREET BREAKFAST : Confidence In Bitcoin Is Back
07/20 Quidel To Acquire Triage Assets From Alere Divestiture
07/20 Abbott's (ABT) CEO Miles White on Q2 2017 Results - Earnings Call Transcript
Financials ($)
Sales 2017 26 458 M
EBIT 2017 5 743 M
Net income 2017 2 755 M
Debt 2017 14 948 M
Yield 2017 2,12%
P/E ratio 2017 42,94
P/E ratio 2018 27,96
EV / Sales 2017 3,90x
EV / Sales 2018 3,62x
Capitalization 88 221 M
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 54,6 $
Spread / Average Target 7,4%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES32.36%88 221
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378
MERCK AND COMPANY6.39%171 303